Home › Non-Small Cell Lung Cancer › California
Non-Small Cell Lung Cancer clinical trials in California
207 studies for Non-Small Cell Lung Cancer are looking for participants at sites in California.
Cities in California
- Los Angeles87 studies
- San Diego48 studies
- Santa Monica45 studies
- San Francisco37 studies
- Baldwin Park36 studies
- Sacramento29 studies
- Orange25 studies
- Irvine25 studies
- Mountain View22 studies
- Santa Rosa17 studies
- Newport Beach14 studies
- Huntington Beach14 studies
- Concord14 studies
- Fullerton13 studies
- Long Beach12 studies
- Torrance11 studies
- Vallejo10 studies
- Roseville10 studies
- Glendale9 studies
- San Bernardino9 studies
- Westminster8 studies
- Anaheim8 studies
- Modesto7 studies
- Richmond7 studies
- San Jose7 studies
- Fresno7 studies
- Burbank6 studies
- Stockton6 studies
- Oakland6 studies
- Santa Clara6 studies
- Fremont6 studies
- Santa Barbara5 studies
- San Leandro5 studies
- Daly City5 studies
- Berkeley5 studies
- Sunnyvale5 studies
- Oxnard5 studies
- San Mateo4 studies
- Lancaster4 studies
- Riverside3 studies
- Yuba City3 studies
- Redwood City3 studies
- Pleasanton3 studies
- Santa Maria3 studies
- Salinas3 studies
- Indio3 studies
- Clovis3 studies
- Norwalk3 studies
- Upland3 studies
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Hoag Hospital Newport Beach, Newport Beach
- University of California, Irvine Health, Orange
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06765109A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 9, La Jolla
- ALX Center 11, Santa Monica
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07085091A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Beverly Hills Cancer Center, Beverly Hills
- Orange Coast Memorial Medical Center, Fountain Valley
- Local Institution - 0027, Los Alamitos
- and 5 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07361510Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Kaiser Permanente-Anaheim, Anaheim
- Kaiser Permanente-Deer Valley Medical Center, Antioch
- Sutter Auburn Faith Hospital, Auburn
- and 56 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT04267848Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC
- Stanford University, Stanford
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT04585490A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
- START LA, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07659782Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Tower Cancer Research Foundation, Beverly Hills
- Cedars-Sinai Medical Center, Los Angeles
- Cedars-Sinai Cancer - Tarzana, Tarzana
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07388524Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Providence - St. Jude Medical Center /ID# 271414, Fullerton
- FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 274450, Oxnard
- UCLA - Santa Monica /ID# 271690, Santa Monica
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06772623A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Duarte
- Research Site, Los Angeles
- Research Site, Newport Beach
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05877599A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Los Angeles
- PHN-012-001 Site, San Diego
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07127874Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- MemorialCare Long Beach Medical Center, Long Beach
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06881784Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Tower Cancer Research Foundation, Beverly Hills
- Kaiser Permanente Dublin, Dublin
- Kaiser Permanente-Fremont, Fremont
- and 20 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06498635A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Providence St. Jude Medical Center ( Site 0106), Fullerton
- VA Long Beach Healthcare System ( Site 0199), Long Beach
- USC Norris Comprehensive Cancer Center ( Site 0205), Los Angeles
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06623422A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Alta Bates Summit Medical Center Comprehensive Cancer Center, Berkeley
- John Muir Health Clinical Research Center, Concord
- UC San Diego Medical Center - Encinitas, Encinitas
- and 16 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07144280A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- University of California at San Diego, La Jolla
- University of California Irvine, Orange
- Stanford Cancer Institute, Stanford
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05498428A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- UC Davis Comprehensive Cancer Center ( Site 3204), Sacramento
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07513376Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
- Providence Medical Foundation, Fullerton
- Providence St. Jude Medical Center - Virginia K. Crosson Cancer Center and Infusion Center, Fullerton
- Providence St. Jude Medical Center, Fullerton
- and 9 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07227298Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Oncura Health - Anaheim, Anaheim
- Memorial Care Orange Coast Medical Center Attn, Fountain Valley
- MemorialCare Orange Coast Medical Center, Fountain Valley
- and 20 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07222566Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Duarte
- Research Site, Los Angeles
- Research Site, Newport Beach
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06218914This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Providence Medical Foundation, Fullerton
- Providence St. Jude Medical Center Virginia K. Crosson Cancer Center and Infusion Center, Fullerton
- Providence St. Jude Medical Center, Fullerton
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06758401A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, La Mesa
- Research Site, Los Alamitos
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06868277A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- The City of Hope Orange County Lennar Foundation Cancer Center, Irvine
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07154290A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Sansum Clinic, Santa Barbara
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Sep 25, 2026 · NCT05920356A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
- City of Hope, Duarte
- City of Hope 1, Irvine
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07586202Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
- Stanford Cancer Institute, Stanford
- Stanford Hospital and Clinics, Stanford
- Stanford Hospital Investigational Drug Services, Stanford
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07489066A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- The Oncology Institute of Hope and Innovation, Cerritos
- City of Hope Corona, Corona
- City of Hope, Duarte
- and 26 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06667076Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- University of California San Diego, La Jolla
- Stanford University, Palo Alto
- UCLA Medical Center, Santa Monica
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04981119A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- City of Hope National Medical Center /ID# 277005, Duarte
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277928, Irvine
- UC San Diego Health - Moores Cancer Center /ID# 278836, La Jolla
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07155187A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Beverly Hills Cancer Center ( Site 0070), Beverly Hills
- UCLA Clinical & Translational Research Center (CTRC) ( Site 0033), Los Angeles
- Hoag Memorial Hospital Presbyterian ( Site 0096), Newport Beach
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06312137A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Moores Cancer Center at UC San Diego Health, La Jolla
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06667908A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- City of Hope, Duarte
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06172478Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0130), Burbank
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06170788A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
- Kivu Trial Site, Santa Monica
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07229313Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- UCLA Hematology/Oncology - Santa Monica, Los Angeles
- Profound Research LLC, Oceanside
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06890598Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Precision NextGen Oncology, Beverly Hills
- OPN Healthcare, Inc, Glendale
- University of Southern California, Los Angeles
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379Pan-tumor MRD Study
- Los Angeles Cancer Network (LACN), Glendale
- Ventura County Hematology Oncology Specialists, Oxnard
- Medical Oncology Associates of San Diego (MOASD), San Diego
- and 2 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06605404Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Los Angeles
RecruitingPhase 2
Ages 18 to 95 · All sexes · Updated Sep 23, 2026 · NCT05061550A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
- Providence Medical Foundation - Fullerton - Virginia K. Crosson Cancer Center, Fullerton
- University of California - Irvine, Orange
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07140016Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Anaheim
- Research Site, Beverly Hills
- Research Site, Fountain Valley
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06357533Intratumoral N17350 in Advanced Solid Tumors
- The Angeles Clinic and Research Institute, Los Angeles
- UCLA - Jonsson Comprehensive Cancer Center, Los Angeles
- Scripps Clinic Torrey Pines - La Jolla, San Diego
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07339176From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.